HLB Life Science Co. Ltd

HLB Life Science Co., Ltd. wholesales and distributes pharmaceuticals in South Korea and internationally. It develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for various cancers; Seclidemstat, an oral epigenetic small molecule for targeted therapy in solid tumors; and Tegavivint, a Wnt/β-catenin inhibitor for desmoid tumors, acute myeloid leukemia, osteosarcoma, and other solid tumors. The company also develops LifeLiver, an extracorporeal bioartificial liver system; HepaStem, a human adult liver-derived progenitor cell therapy; and HLBLS-200, a biocompatible polysaccharide-based powder that forms adhesive hemostasis on contact with blood. It is also involved in waste heat recovery, cogeneration, facility installation, solar and photovoltaic power, bioenergy, geothermal, waste energy, wind power, and fuel cell businesses, as well as energy efficiency and heating system improvement projects. Formerly Energy Solutions Co., Ltd., it changed its name to HLB Life Science Co., Ltd. in December 2015, was founded in 1998, and is headquartered in Hwaseong, South Korea.